Key result
PCSK9 inhibitors linked to ~170% increase in circulating endothelial progenitor cells.
Why the study?
Does PCSK9 monoclonal antibody therapy improve circulating endothelial progenitor cell levels and function in adults with hypercholesterolemia and cardiovascular disease?
Observational (n=51)
Does PCSK9 monoclonal antibody therapy improve circulating endothelial progenitor cell levels and function in adults with hypercholesterolemia and cardiovascular disease?
Answers are grounded in this paper and cite their sources.
PCSK9 monoclonal antibodies increase circulating endothelial progenitor cell levels and function in patients with cardiovascular disease, suggesting a novel pleiotropic class effect.
• Circulating endothelial progenitor cells (cEPCs) have a crucial role in vascular repair. • Among patients with cardiovascular disease PCSK9 mAb initiation is associated with an increase in cEPCs levels and function. • These findings persist in both evolocumab and alirocumab. • The increase in cEPCs with PCSK9 mAb suggest a novel pleiotropic class effect. The role of circulating endothelial progenitor cells (cEPCs) in vascular repair and their association to cardiovascular protection is well established. We examined the effect of proprotein convertase subtilisin kexin type 9 monoclonal antibodies (PCSK9 mAb) on cEPCs in adults with hypercholesterolemia and cardiovascular disease, aiming to establish a pleotropic class effect. Non-interventional prospective study in patients with cardiovascular disease treated with either evolocumab or alirocumab. Patients were sampled for cEPCs at baseline, 1- and 3-months following initiation of PCSK9 mAb. cEPCs were assessed using flow cytometry by expression of CD34/CD133 and vascular endothelial growth factor receptor (VEGFR)-2, and functionally by formation of colony forming units (CFUs) and by Mitochondrial Tetrazolium (MTT) assay, indicative of cEPCs viability. 51 patients (median age 67 (IQR 63,74) years;63 % male, median low-density lipoprotein-cholesterol (LDL-C) 125 (102,165) mg/dL) were initiated on PCSK9 mAb therapy (evolocumab n = 22, alirocumab n = 29) for secondary prevention. Following 3-month treatment with PCSK9 mAb, there was an increase in CD34 (+) VEGFR-2 (+) and CD133 (+) VEGFR-2 (+) levels (0.50 % [IQR 0.30,1.04] to 1.36 % [0.89, 1.73], p < 0.001 and 0.57 % [0.25,0.88] to 1.18 % [0.74,1.66], p < 0.001, respectively). Functionally, increase in EPCs-CFUs was evident (0.5 [0.0,1.0] to 2.0 [1.5,2.5], p < 0.001) with concomitant increase in MTT (0.11 [0.09,0.15] to 0.17 [0.12,0.21], p < 0.001). Stratifying by PCSK9 mAb, both agents were associated with an increase in cEPCs level and function. In hypercholesterolemic patients with cardiovascular disease treated with PCSK9 mAb, there is an increase in cEPCs levels and function from baseline levels. These findings, which persist in both evolocumab and alirocumab, might suggest a novel pleiotropic class effect.
No takes yet. Share an insight, caveat, or question.
Gurevitz et al. (2024) conducted an observational in Hypercholesterolemia and cardiovascular disease (n=51). PCSK9 monoclonal antibodies (evolocumab or alirocumab) vs. Baseline was evaluated on CD34(+) VEGFR-2(+) circulating endothelial progenitor cell levels (p=<0.001). PCSK9 monoclonal antibody therapy in patients with cardiovascular disease increased CD34(+) VEGFR-2(+) circulating endothelial progenitor cell levels from 0.50% to 1.36%.
Synapse has enriched 10 related papers. Consider them for comparative context: